Phase 2TerminatedAge-related condition
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
- Sponsor
- Pliant Therapeutics, Inc. (Industry)
- Enrollment
- 320 enrolled
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809; Placebo
- Ages
- adults, older adults
- Registry
- NCT06097260
Full record on ClinicalTrials.gov
From the registry
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Primary outcomes
- Change From Baseline in Forced Vital Capacity at Week 52
History
Results first posted
Last registry update
Primary completion
Started
Registered